融券方面，当日融券卖出0.11万股，净卖出0.10万股。 来源：金融界 7月31日，沪深两融数据显示，美好医疗获融资买入额0.11亿元，居两市第2623位，当日融资偿还额0.11 亿元，净买入6.70万元。 最近三个交易日，29日-31日，美好医疗分别获融资买入0.14亿元、0.14亿元、0.11亿元。 ...

7月30日，沪深两融数据显示，美好医疗获融资买入额0.14亿元，居两市第2417位，当日融资偿还额0.13 亿元，净买入55.72万元。 最近三个交易日，28日-30日，美好医疗分别获融资买入0.05亿元、0.14亿元、0.14亿元。 融券方面，当日融券卖出0.00万股，净买入0.97万股。 来源：金融界 ...

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Meihao Medical (301363), indicating a slight decline in stock price and a mixed financial outlook for the first quarter of 2025 [1][3] - As of July 29, 2025, Meihao Medical's stock closed at 19.0 yuan, down 0.89%, with a turnover rate of 4.85% and a trading volume of 75,700 hands, amounting to a transaction value of 143 million yuan [1] - The company experienced a net outflow of main funds amounting to 13.99 million yuan, representing 9.78% of the transaction value, with significant outflows from large and medium orders [1] Group 2 - For the first quarter of 2025, Meihao Medical reported total operating revenue of 296 million yuan, reflecting a year-on-year growth of 5.05%, while net profit attributable to shareholders decreased by 10.62% to 51.88 million yuan [1] - The company's financial ratios indicate a current ratio of 5.964, a quick ratio of 5.060, and a debt-to-asset ratio of 12.08%, suggesting a strong liquidity position [1] - Meihao Medical, established in 2010 and based in Shenzhen, has a registered capital of 406.66 million yuan and a paid-in capital of 321.16 million yuan [1][2]

Group 1 - The medical device industry experienced a decline of 0.17% on July 29, with a net outflow of 351 million yuan in main funds, where 55 stocks rose and 43 fell [1] - The companies with the highest net outflow of main funds included Yirui Technology (14.03 million yuan), Meihao Medical (13.99 million yuan), Aohua Endoscopy (13.90 million yuan), Kangzhong Medical (13.42 million yuan), and Microelectrophysiology (12.50 million yuan) [1] Group 2 - Notable stock performance included BGI Genomics with a price of 53.69 and a rise of 3.17%, attracting a net inflow of 745.64 million yuan, representing 10.25% of the main fund [2] - Other companies with significant movements included Nanwei Medical, which fell by 1.27% to 84.08, with a net inflow of 535.99 million yuan (11.35%); Sanofi Biological, which dropped by 6.62% to 21.44, with a net inflow of 507.66 million yuan (6.33%); and Haooubo, which rose by 2.86% to 124.82, with a net inflow of 426.62 million yuan (18.96%) [2]

Summary of Key Points Core Viewpoint The company, Shenzhen Meihua Chuangyi Medical Technology Co., Ltd., has approved an increase in the guarantee limits for its subsidiaries to support their operational and business development needs, with a total guarantee amount not exceeding RMB 1 billion. Group 1: Guarantee Adjustments - The company and its subsidiaries have approved a total guarantee amount of up to RMB 1 billion, which includes guarantees for Huizhou Meihua, Malaysia Meihua, and Malaysia Miman [1][2][9] - The specific guarantees include RMB 300 million for Huizhou Meihua, RMB 200 million for Malaysia Meihua, and RMB 500 million for Malaysia Miman [1][2] Group 2: Subsidiary Information - Huizhou Meihua was established on April 12, 2018, with a registered capital of RMB 900 million, focusing on medical device production and sales [3][5] - Hong Kong Meihua, established on March 20, 2015, has a registered capital of HKD 80 million and is a wholly-owned subsidiary [5] - Malaysia Meihua, established in December 2015, has a registered capital of RM 41.16 million and is involved in the manufacturing and sales of medical devices [5][6] - Malaysia Miman, established on May 30, 2023, has a registered capital of RM 23.325 million and focuses on manufacturing plastic products [7] Group 3: Financial Indicators - As of March 31, 2025, Huizhou Meihua reported total assets of RMB 150.12 million and net assets of RMB 128.09 million [5] - Hong Kong Meihua reported total assets of RMB 62.03 million and net assets of RMB 32.77 million [5] - Malaysia Meihua reported total assets of RM 50.10 million and net assets of RM 35.88 million [6] - Malaysia Miman reported total assets of RM 29.21 million and net assets of RM 16.49 million [8] Group 4: Guarantee Agreement Details - The guarantees are expected and the related agreements have not yet been signed, with terms to be negotiated with creditors [8] - The board believes that these guarantees will not adversely affect the company, as it maintains control over the subsidiaries [8][9]

Core Points - The company announced an adjustment to the expected guarantee amount for itself and its subsidiaries, totaling up to 1.8 billion RMB, which represents 51.73% of the audited net assets as of the end of 2024 [1][2] - The adjustment includes additional subsidiaries such as Hong Kong Meihao, Cayman Meihao, and Singapore Meihao, expanding the scope of the guarantees [1] - As of June 30, 2025, the outstanding guarantee balance is 41 million RMB, accounting for 1.18% of the audited net assets as of the end of 2024 [1] Summary by Sections Guarantee Amount Adjustment - The company held a meeting on July 24 to review and approve the adjustment of the expected guarantee amount, which now totals 1.8 billion RMB [1] - The guarantees include amounts for Huizhou Meihao (up to 300 million RMB), Malaysia Meihao (up to 200 million RMB), and Malaysia Miman (up to 500 million RMB) [1] Subsidiaries Involved - The adjustment includes guarantees for wholly-owned subsidiaries such as Hong Kong Meihao, Cayman Meihao, and Singapore Meihao, among others [1] - The announcement provided details on the subsidiaries, including establishment dates, registered capital, and recent financial data [1] Risk Management - The board believes that the guarantees are necessary to meet the funding needs of the subsidiaries for their production and business development [2] - The company has not provided guarantees for companies outside the consolidated financial statements and has no overdue external guarantees [2]

证券代码：301363 证券简称：美好医疗 公告编号：2025-046 深圳市美好创亿医疗科技股份有限公司 第二届监事会第十六次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 具体内容详见公司于同日在巨潮资讯网（www.cninfo.com.cn）披露的相关 公告。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交公司 2025 年第一次临时股东大会审议。 三、备查文件 1、公司第二届监事会第十六次会议决议。 一、监事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届监事会 第十六次会议通知于2025年7月21日以书面、电话等方式送达全体监事，并于2025 年7月24日在公司会议室召开现场会议。本次会议由监事会主席黎莎女士主持， 会议应到监事3人，实到监事3人，会议的召集和召开符合《中华人民共和国公司 法》《公司章程》等相关规定。 二、监事会会议审议情况 经全体与会监事认真审议、充分讨论，会议审议并通过了以下议案： （一）审议通过《关于调整公司及控股子公司预计担保额度的议案》 经审核，监事会认为：本次 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届董事会 第十九次会议通知于 2025 年 7 月 21 日以书面、电子邮件及电话等方式送达全体 董事，并于 2025 年 7 月 24 日在公司会议室以现场结合通讯方式召开。会议应参 加董事 9 人，实际参会董事 9 人，其中 Florian Then 先生、Joel Chan 先生、 王建新先生、梁永晔先生、吴学斌先生、孙超先生以通讯方式参会。本次会议由 董事长熊小川先生召集并主持。经全体与会董事确认，本次会议的召集、召开以 及审议程序符合《公司法》《公司章程》和《董事会议事规则》等有关规定，会 议形成的决议合法、有效。 二、董事会会议审议情况 经全体与会董事认真审议、充分讨论，会议审议并通过了以下议案： （一）审议通过《关于调整公司及控股子公司预计担保额度的议案》 根据公司及子公司战略发展规划及生产经营需要，董事会同意增加担保对象 并调整公司及控股子公司向全资子公司提供的预计担保额度，累计提供最高不超 过人民币18亿元或等值外 ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-047 深圳市美好创亿医疗科技股份有限公司 关于调整公司及控股子公司预计担保额度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、预计担保额度调整情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"或"美好医疗"） 于2025年4月16日召开第二届董事会第十六次会议及第二届监事会第十三次会 议，于2025年5月8日召开2024年年度股东大会，分别审议通过了《关于公司及控 股子公司向银行等金融机构申请授信额度暨担保额度预计的议案》。同意公司及 控股子公司为公司的全资子公司惠州市美好创亿医疗科技有限公司（以下简称 "惠州美好"）提供不超过人民币3亿元或等值外币金额的担保、为美好医疗（马 来西亚）有限公司（以下简称"马来美好"）提供不超过人民币2亿元或等值外 币金额的担保、为米曼（马来西亚）有限公司（以下简称"马来米曼"）提供不 超过人民币5亿元或等值外币金额的担保，累计提供最高不超过人民币10亿元或 等值外币金额的担保。具体内容详见公司于2025年4月18日在巨潮资讯网 （www.cn ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-048 深圳市美好创亿医疗科技股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届董事会第 十九次会议决定于2025年8月11日（星期一）下午15:30召开2025年第一次临时股东 大会（以下简称"本次股东大会"），本次股东大会采取现场投票和网络投票相结合 的方式召开，现将有关事项提示如下： 一、召开会议的基本情况 1.股东大会届次：2025年第一次临时股东大会 2.股东大会的召集人：公司董事会 3.会议召开的合法、合规性：本次会议召开符合有关法律、行政法规、部门规 章、规范性文件、深圳证券交易所业务规则和《公司章程》等的规定。 4.会议召开的日期、时间 （1）现场会议时间：2025年8月11日（星期一）下午15:30 （2）网络投票时间：2025年8月11日（星期一）。其中，通过深圳证券交易所交 易系统进行网络投票的时间为2025年8月11日上午9:15-9:25、9:30-11:3 ...